“Plaintiff Celgene Corporation (“Celgene”) and Defendant USV Private Limited (“USV”), the parties in the above-captioned action, hereby stipulate and consent to entry of judgment and an injunction in this action as follows: IT IS this 6th day of November, 2025: ORDERED, ADJUDGED, AND DECREED as follows: 1. This Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties for purposes of this action only, including as set forth below in Paragraph 6 of this Consent Judgment. As used in this Consent Judgment, the term “USV ANDA Product” shall mean a drug product manufactured, imported, used, sold, offered for sale, marketed, or distributed pursuant to Abbreviated New Drug Application No. 220322 in or for the United States of America, including its territories, possessions, and the Commonwealth of Puerto Rico. 3. As used in this Consent Judgment, the term “Patents-in-Suit” shall mean U.S. Patent Nos. 8,828,427; 9,993,467; and 10,555,939. 4. Until expiration of the Patents-in-Suit, including all extensions and pediatric exclusivities, USV, including any of its successors and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any third party on its behalf, by making, having made, using, selling, offering to sell, importing, or distributing of the USV ANDA Product in or for the United States of America, including its territories, possessions, and the Commonwealth of Puerto Rico, unless and to the extent otherwise specifically authorized by Celgene, and is further enjoined from assisting or cooperating with any third parties in connection with any infringement of the Patents-in-Suit by any such third parties in connection with making, having made, using, selling, offering to sell, importing, or distributing of any pomalidomide-containing drug product that references NDA 204026 in or for the United States of America, including its territories, possessions, and the Commonwealth of Puerto Rico, unless and to the extent otherwise specifically authorized by Celgene. 5. Compliance with this Consent Judgment may be enforced by Celgene and its respective successors in interest or assigns. 6. This Court retains jurisdiction to enforce the terms of this Consent Judgment and to enforce and resolve any disputes related thereto. All claims, counterclaims, affirmative defenses and demands pertaining to the Patents-in-Suit are hereby dismissed with prejudice and without costs, disbursements or attorneys’ fees to any party. 8. Nothing herein prohibits or is intended to prohibit USV from maintaining any “Paragraph IV Certification” pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) or pursuant to 21 C.F.R. § 314.94(a)(12) with respect to the Patents-in-Suit. 9. Nothing herein prohibits or is intended to prohibit USV from engaging in any activity permitted under 35 U.S.C. § 271(e)(1). 10. Nothing herein restricts or is intended to restrict the U.S. Food and Drug Administration from approving Abbreviated New Drug Application No. 220322 or the USV ANDA Product.”